First-line pembrolizumab plus chemotherapy significantly improves outcomes in advanced NSCLC

The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers report.